Agentix Corp. Discloses Substantial Going Concern Doubt, Zero Revenue, and Material Internal Control Weaknesses in Annual Report
AGTX sits 41% above its 52-week low of $0.014 on elevated volume (8.6× avg).
Summary
Agentix Corp.'s annual report confirms severe financial distress with going concern doubt, zero revenue, critically low cash, and material weaknesses in internal controls, signaling an extremely challenging future.
Key Events · Corporate Governance and Compliance · AGTX
-
Substantial Doubt About Going Concern
Both management and the independent auditor explicitly state substantial doubt about the company's ability to continue as a going concern due to accumulated deficits, net losses, and negative cash flows from operations.
-
Zero Revenue and Significant Losses
The company reported no revenues for the fiscal years ended March 31, 2026, and 2025, with a net loss of $485,636 for 2026, indicating a complete lack of operational income.
-
Critically Low Cash Position
Agentix Corp. ended the fiscal year with only $771 in cash, insufficient to support daily operations and fund its business plan for the next 12 months.
-
Material Weaknesses in Internal Controls
Management concluded that disclosure controls and internal control over financial reporting were not effective, citing a lack of a functioning audit committee, inadequate segregation of duties, and ineffective period-end financial reporting processes.
Analysis · AGTX · Life Sciences
Agentix Corp.'s annual 10-K filing reveals a company in severe financial distress, with both management and its independent auditor expressing substantial doubt about its ability to continue as a going concern. The company reported zero revenue for the second consecutive year and a net loss of $485,636, while holding only $771 in cash against $3.6 million in current liabilities. Compounding these financial woes are critical governance issues, including ineffective disclosure controls and internal control over financial reporting, and a lack of an independent audit committee. The company operates with no full-time employees and relies heavily on related-party funding, with significant debt secured by all company assets. This report confirms a dire financial and operational outlook, highlighting systemic issues that pose an existential threat to the company.
At the time of this filing, AGTX was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $801.3K. The 52-week trading range was $0.01 to $0.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.